Head and neck cancers (HNCs) are on the rise and have led to the development of a massive market offering treatments and therapies for the same. A new report, titled ‘EpiCast Report: Head and Neck Cancers - Epidemiology Forecast To 2024,’ now available on MarketResearchReports.biz studies the state of the market in detail.
The report primarily offers a comprehensive overview of the comorbidities and risk factors associated with head and neck cancers. Moreover, the historical trends associated with these cancer types are also studied in detail. By focusing on the seven major markets of the world-France, the United States, Germany, Spain, Italy, Japan, and the United Kingdom-the report provides a 10-year epidemiological projection of diagnosed incident cases. These cases have been classified into three sub-groups – lip, pharynx, and oral cavity cancers; sinuses, nose, and related cancers; and larynx cancers.
Furthermore, the report also includes a five-year diagnosis of prevalent thyroid cancer cases in the seven major markets. For a detailed study of the diagnosed incident thyroid cancer and HNCs, the report segments the cases based on clinical stage at diagnosis, age, sex, and histology. The report has been prepared by a team of expert epidemiologists at the PhD and Masters level.
According to the report, the number of people suffering from head and neck cancers is expected to rise over the forecast period of the report. HNCs are becoming increasingly common across the world, with about 600,000 new cases reported worldwide every year. Authors of the report expect that in the seven major markets alone, the number of diagnosed incident cases of head and neck cancers will rise to 174,056 by 2024 from an estimated 151,393 in 2014. The report forecasts this to happen at an AGR of 1.50% over the forecast period of the report.
The report also states that by 2024, the United States will have the highest HNC cases among all the 7MMs. The number of diagnosed incident cases of head and neck cancers in the United States, by 2024, will be 65,663. At the far end of the spectrum will be the United Kingdom, with about the number of diagnosed incident cases of HNCs projected to stand at 12,702 by 2024.
Likewise, the number of diagnosed incident cases of thyroid cancer will also rise substantially over the report’s forecast period. In 2014, 7MMs were expected to collectively see 93,225 diagnosed incident cases; the number will soar to 123,504 by 2024, translating into an annual growth rate of 3.25% through the report’s forecast period. While the United States will lead in thyroid cancer cases, Spain is expected to have the lowest number of people diagnosed with thyroid cancer, says the report.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org